Xantho Biotechnology attended Bio Japan 2024 for global business partnering
The CEO and BD manager of Xantho Bio. attended Bio Japan 2024, one of the largest Bio convention in Asia, held in PACIFICO Yokohama Convention Center, Japan (from October 9 to October 11). During the 3-day event, Xantho Bio. participated in the one-on-one partnering meetings with international pharmaceutical companies to discuss drug licensing opportunities. Our leading product, GM-XANTHO, a botanical new drug for topical use developed by Xantho Bio., is used for the treatment of atopic dermatitis, with plans for out-licensing following the phase IIa clinical trial unblinding in Q1 2025.
Xantho Bio BD Manager and members of the Biotechnology and Pharmaceutical Industries Development Office (BPIPO)
The Bio Japan Taiwanese delegation was led and organized by BPIPO, assisting Taiwanese biotech companies, including Xantho Bio. to increase visibility in the global market, thereby facilitating global business partnering.
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
